[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-chronic":24},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,53,0,25,[9,38,72,98,124,160,190,217,245,270,295,319,344,376,401,422,446,475,504,529,550,583,608,633,656],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100054213","using-technology-to-track-pain-and-pain-related-outcomes-100054213",false,"NCT04267588","Using Technology to Track Pain and Pain-related Outcomes","Inclusion Criteria:\n\n* ≥ 21 years of age\n* Pain duration \\> 3 months\n* Average pain level of \\>3 out of 10 (0=no pain; 10=worst pain imaginable)\n* English fluency\n* Are not scheduled to undergo any medical procedures during the course of the study\n* Have a physician-confirmed medical diagnosis associated with chronic pain\n* Are willing to comply with the study protocol and give written informed consent. Patients taking non-narcotic analgesics must be on a stable dose one month prior to participation.\n\nExclusion Criteria:\n\n* Delirium, dementia, or cognitive impairment (i.e., Mini Mental State Exam score \\\u003C24)\n* Unstable major psychiatric disorder or history of schizophrenia\n* Beck Depression Inventory score \\>30 or report of suicidal ideation\n* Active substance abuse;\n* Refusal to provide access to relevant medical record information.","ALL","21 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Persistent pain is a public health epidemic. The current protocol seeks to develop technology to aid patients' tracking of patients' pain, medications and pain-related variables. The investigators seek to talk with patients in co-investigator's clinic to solicit feedback, as well as pilot test the technology with pain patients.",[24],"Pain, Chronic","RECRUITING","2026-07-10",{"date":28,"type":29},"2026-07-13","ACTUAL",{"date":31,"type":29},"2020-08-10",{"date":33,"type":20},"2027-06-30",{"name":35,"class":36},"Johns Hopkins University","OTHER",1,{"id":39,"slug":40,"hasResults":12,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100054130","rutiss-diary-and-rutiss-65-study-100054130","NCT07698041","RUTISS-Diary and RUTISS-65 Study","Developing and Validating Two New Patient-Reported Outcome Measures of Recurrent Urinary Tract Infection Symptoms: A Symptoms Diary and Adapted Measure for Older Adults","Inclusion for RUTISS-Diary:\n\n* Participants must be 18 years and older\n* All participants must have native\u002Fbilingual or advanced fluency in English.\n* Access to a computer\u002Fmobile device for survey completion.\n* Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).\n\nInclusion for RUTISS- 65:\n\n* Participants must be 65 years and older\n* Access to a computer\u002Fmobile device for survey completion, paper copy available upon request.\n* All participants must have native\u002Fbilingual or advanced fluency in English.\n* Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).\n\nExclusion criteria (for RUTISS-Diary and RUTISS-65)\n\n* Participants must not report a current diagnosis of interstitial cystitis (measured in demographics questionnaire).\n* Symptoms of cognitive confusion or dementia.\n* No active malignancy e.g. bladder or prostate cancer\n* Participants must not report beginner or intermediate level fluency in English. Future work will be done to translate the PROMs into alternative languages.\n* In addition to the interstitial cystitis exclusion question, participants will also be asked in the demographic questionnaire if they are pregnant or have an indwelling catheter or use intermittent self-catheterisation. Participants who report \"yes\" to either of these will be excluded from participation.","18 Years",{"count":47,"type":20},200,"Existing patient-reported outcome measures assess acute urinary tract infection but do not support daily symptom tracking in recurrent UTI (rUTI) or meet the needs of older adults. This single-site study will develop and validate two adapted measures: the RUTISS-Diary for daily symptom monitoring and the RUTISS-65 for reporting symptoms in adults aged 65 years and over. Approximately 200 participants with rUTI will complete the RUTISS-Diary daily for 7 days and again on day 14. Participants aged 65 years and over will also complete the RUTISS-65 on days 1 and 2 to assess its reliability and validity.",[50,51,52,24],"Urology","Urological Diseases","Patient Satisfaction",[54,55,56,57,58,59,60,61],"recurrent urinary tract infection","rUTI","outcome measure","PROMs","urinary","UTI","burden","assessment tools","NOT_YET_RECRUITING","2026-07-06",{"date":28,"type":29},{"date":66,"type":20},"2026-07-08",{"date":68,"type":20},"2027-12-24",{"name":70,"class":36},"Katherine Finlay",2,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":16,"minAge":79,"maxAge":45,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":37},"100366076","pain-and-weight-treatment-development-and-trial-of-paw-100366076","NCT04046562","Pain and Weight Treatment: Development and Trial of PAW","PAW","Inclusion Criteria:\n\n* Males and females between 12 and 18 years of age\n* Ability to speak, write and read English\n* A parent or guardian who speaks, writes and reads English\n* Signed consent and assent from the child and parent\n* Enrollment in a weight management program\n* Score greater than 3 on the Pain Burden Inventory at screening (in order to recruit adolescents who experience more than just general aches and pains).\n* Youth reporting musculoskeletal pain\n\nExclusion Criteria:\n\n* Parent or guardian unable to participate\n* Patients on weight reducing medications\n* Severe psychiatric illness (i.e., suicidal or hospitalization within past 6 months)\n* Medical conditions such as Type 1 diabetes","12 Years",{"count":81,"type":20},50,"INTERVENTIONAL",[84],"NA","Pediatric weight management efficacy is impacted by failure to complete treatment protocols and, for those that do complete treatment, a return to unhealthy behaviors. This project tests whether treating pain, a common comorbid condition to pediatric obesity, will enhance treatment. This study will generate results that can be translated into immediate improvements in care for families seeking treatment for pediatric obesity.",[87,24,88],"Obesity, Adolescent","CBT","2026-06-29",{"date":91,"type":29},"2026-07-01",{"date":93,"type":29},"2019-08-14",{"date":95,"type":20},"2027-06",{"name":97,"class":36},"Connecticut Children's Medical Center",{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":82,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100429589","phase-3-prevention-of-persistent-pain-with-lidocaine-infusions-in-breast-cancer-surgery-plan-100429589","NCT04874038","Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Undergoing a unilateral or bilateral lumpectomy or mastectomy, inclusive of all pathologies, including prophylactic surgery (e.g., family history or BRCA gene mutation)\n\nExclusion Criteria:\n\n1. Previous breast surgery within 6 months of index surgery\n2. Undergoing any autologous flap procedure during index surgery\n3. Presence known chronic pain disorder involving surgical site or ipsilateral chest wall, shoulder, or arm during the 3-months prior to index surgery\n4. Documented hypersensitivity or allergy to lidocaine\n5. Surgery not planned to be performed under general anesthesia and\u002For planned use of regional or neuraxial anesthetic techniques before surgery (i.e., epidural, paravertebral, serratus plane block, pectoralis or modified pectoralis block)\n6. History of ventricular tachycardia, ventricular fibrillation, or atrioventricular block without a pacemaker\n7. Known cirrhotic liver disease\n8. Pregnant\n9. Unlikely to comply with follow-up (e.g. no fixed address, language difficulties that would impede valid completion of questionnaires, plans to move out of town)","100 Years",{"count":106,"type":20},1602,[108],"PHASE3","Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months after breast cancer surgery.",[111,112,113,24],"Post-mastectomy Pain Syndrome","Breast Cancer","Pain, Postoperative","2026-06-17",{"date":116,"type":29},"2026-06-22",{"date":118,"type":29},"2021-09-22",{"date":120,"type":20},"2026-11-01",{"name":122,"class":36},"University Health Network, Toronto",17,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":82,"phases":136,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":37},"100555487","the-proactive-study-for-black-elders-100555487","NCT06512727","The PROACTIVE Study for Black Elders","Testing the Pain Relief of musculOskeletal Conditions and Arthritis Using Carefully Tailored InterVEntions (PROACTIVE) Intervention: A Randomized Controlled Trial","PROACTIVE","Inclusion Criteria:\n\n1. Self-identify as being part of the Black American diaspora (Black\u002FAfrican American, Afro-Caribbean)\n2. Age 50-92 years\n3. Self-report chronic musculoskeletal pain (CMP) as defined as persistent or recurrent pain lasting 6 months or longer that arises as part of a disease or injurious process directly affecting bone(s), joint(s), muscle(s), or related soft tissue(s)\n4. Self-report a chronic musculoskeletal condition (e.g., osteoarthritis, chronic low back pain) in at least one lower extremity joint (hip, knee, low back, or ankle pain)\n5. Report chronic musculoskeletal symptoms: aching, stiffness, or swelling in a major lower extremity joint or low back on most days (4-5\u002F7) of the week\n6. Have (or be eligible for) a healthcare insurance plan in the state of Florida (Medicare, Medicaid, Medicare Advantage plans, Blue Cross\u002FBlue Shield, Humana, Aetna, etc.)\n7. Able to read, write, and understand English at sixth-grade level\n\nExclusion Criteria:\n\n1. Unwilling to be randomized to either study arm\n2. Self-reported diagnosis of sickle cell disease or related thalassemias\n3. History of major neurological event (e.g., stroke) or current neurological disease (e.g., Parkinson's disease, multiple sclerosis, epilepsy)\n4. Major cardiovascular problem in the past 6 months that would cause shortness of breath and\u002For chest pain (e.g. myocardial infarction, coronary artery bypass graft, or valve replacement, pulmonary embolism or deep venous thrombosis) or uncontrolled Hypertension (Systolic Blood Pressure (SBP) \\> 170 mmHg, Diastolic Blood Pressure (DBP) \\> 90 mmHg) OR Hypotension (SBP \\\u003C90 mmHg, DBP \\\u003C60 mmHg)\n5. Currently undergoing curative or palliative chemotherapy or radiation for active cancer\n6. Severe physical impairment (e.g., a major activity of daily living disability requiring use of wheelchair as primary method of mobility, or unable to dress, bath, use the toilet, or transfer independently)\n7. Serious mental health disorder requiring hospitalization within past 12 months\n8. Severe sensory deficit (severe hearing loss or blindness)","50 Years","92 Years",{"count":135,"type":20},120,[84],"Chronic musculoskeletal pain (CMP), while a leading cause of physical disablement, is a neglected national health disparity issue in Black communities. The purpose of this study is to test a novel culturally congruent pain self-management intervention. A total of 120 persons aged 50-92, self-identifying as Black or African American having CMP will be invited to participate in this study. The primary outcome measured throughout this 3-year study is movement-evoked pain (MEP).",[139,140,141,24,142],"Musculoskeletal Pain","Chronic Pain","Osteoarthritis","Movement Evoked Pain",[144,145,146,147,148,149,150],"chronic musculoskeletal pain","chronic pain","Black","African Americans","pain self-management","prayer","social determinants of health","2026-06-02",{"date":153,"type":29},"2026-06-04",{"date":155,"type":29},"2025-05-07",{"date":157,"type":20},"2027-10-01",{"name":159,"class":36},"University of Florida",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":82,"phases":170,"briefSummary":171,"conditions":172,"keywords":176,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":37},"100513156","offset-mechanisms-in-evaluation-of-lumbar-medial-branch-blocks-100513156","NCT05961800","Offset Mechanisms in Evaluation of Lumbar Medial Branch Blocks","OMEGA Study: Offset Mechanisms in Evaluation of Lumbar Medial Branch Block","OMEGA","Inclusion Criteria:\n\n* Scheduled for lumbar MBB in UPMC Pain Management clinics\n* Age \\> 18 years old\n* Predominantly axial chronic low back pain at least 3 months on a daily basis\n* Must meet the minimum criteria for cognitive function using the PROMIS 2-item cognitive screener (\\>3)\n* Low back pain intensity of \\> 3\u002F10\n* Willing and able to receive study-related phone calls\n\nExclusion Criteria:\n\n* History of spine surgery at the level of the lumbar MBB\n* Active worker's compensation or litigation claims\n* New pain and\u002For psychiatric treatments within 2 weeks of enrollment\n* Not fluent in English and\u002For not able to complete the questionnaires\n* Any clinically unstable systemic illness that is judged to interfere with the study",{"count":169,"type":20},40,[84],"This study examines the relationship between central nervous system (CNS) mechanisms of pain inhibition and the pain relief that occurs following a lumbar medial branch block (MBB).",[24,173,174,175],"Facet Joint Pain","Pain, Procedural","Analgesia",[177,178,179,180,181,182],"lumbar","medial branch block","offset analgesia","onset hyperalgesia","QST","quantitative sensory testing",{"date":153,"type":29},{"date":185,"type":29},"2023-07-05",{"date":187,"type":20},"2028-06",{"name":189,"class":36},"University of Pittsburgh",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":82,"phases":199,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":37},"100532471","phase-2-mivetscan-cannabidiol-cbd-care-trial-100532471","NCT06213233","MIVetsCan: Cannabidiol (CBD)-Care Trial","Pragmatic Trial of Cannabidiol to Improve Chronic Pain Symptoms Among Veterans","Inclusion Criteria:\n\n* Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures\n* Armed Services Veteran\n* All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.\n* Reports moderate to severe chronic pain defined by protocol\n* Currently using or interested in using cannabis for pain management\n* Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention\n* Individuals of reproductive potential must agree to use acceptable birth control per protocol\n* Participants must also agree not to donate sperm or eggs during study drug administration\n* Willingness to attend all study visits (may be done virtually)\n* Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen\n* Willingness to wear Fitbit or other similar sensor for passive-data collection\n* Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use\n\nExclusion Criteria:\n\n* Not an Armed Services Veteran\n* Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)\n* Participant reports pregnancy or are nursing\n* Planning to move out of a state with legal recreational marijuana use during course of study\n* Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol\n* Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol\n* Participation in any other clinical trials over the course of this study\n* Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)\n* Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)\n* Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures\n* Recent\u002Fnew diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated)\n* Current valproate and clobazam use per self-report or medical records\n* Self-reported allergies to sesame oil or cannabis\u002Fcannabinoids",{"count":198,"type":20},468,[200],"PHASE2","This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.\n\nEligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.\n\nThe study hypotheses:\n\n\\- CBD would improve overall pain symptoms compared to placebo",[24],[204,205,206,207],"Cannabidiol (CBD)","Veterans","Surveys","Fitbit wearable","2026-05-29",{"date":210,"type":29},"2026-06-01",{"date":212,"type":29},"2024-02-12",{"date":214,"type":20},"2028-12",{"name":216,"class":36},"Kevin Boehnke",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":82,"phases":227,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100486336","comparative-effectiveness-of-online-8-session-cbt-vs-1-session-empowered-relief-for-chronic-pain---the-progress-study-100486336","NCT05612750","Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study","Comparative Effectiveness of Online Cognitive Behavioral Therapy vs. An Online Single-Session Pain Relief Skills Class for Chronic Pain - The PROGRESS Study","PROGRESS","Inclusion Criteria:\n\n1. At least 18 years of age or older of either sex (and all genders).\n2. Chronic pain (pain that occurs on at least half of the days of 3 months or more).\n3. Past-month average pain intensity score of at least 3\u002F10.\n4. Ability to adhere to and complete study protocols.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Cognitive impairment, non-English speaking, or psychological factors that would preclude comprehension of material and\u002For full participation in the study including group treatment.\n3. Active suicidality documented in medical records.\n4. Study staff may exclude individuals with a known history of disruptive behavior to minimize contamination of the learning environment for an entire treatment cohort.\n5. Receipt of either study treatment in the past 3 months.",{"count":226,"type":20},1650,[84],"The purpose of this study is to conduct a pragmatic clinical trial comparing the effectiveness of: (1) 8-week cognitive behavioral therapy for chronic pain (pain-CBT; sixteen hours total treatment time); and (2) a 1-session pain relief skills intervention for chronic pain (Empowered Relief; two hours total treatment time).",[24,230,231],"Lupus","Pelvic Pain",[233,230,231,234],"Young adult","Behavioral Health","2026-05-07",{"date":237,"type":29},"2026-05-11",{"date":239,"type":29},"2023-01-01",{"date":241,"type":20},"2029-05-01",{"name":243,"class":36},"Stanford University",5,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":252,"minAge":45,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":82,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":37},"100547208","opioid-free-anaesthesia-in-breast-cancer-surgery-100547208","NCT06404983","Opioid-free Anaesthesia in Breast Cancer Surgery","A Comparative Evaluation of Opioid Free Anaesthesia Technique Versus the Conventional Technique in Oncological Breast Surgery","Inclusion Criteria:\n\n* adult patients\n* breast cancer surgery (mastectomy, lumpectomy, with or without lymph node excision) under general anaesthesia\n\nExclusion Criteria:\n\n* under 18 years\n* patient refusal\n* opioid use (systemic or not) for any reason (e.g., chronic malignant pain)\n* language barrier (difficulty in communicating in Greek language)\n* allergy to the administered agents\n* severe arrhythmia or other serious cardiac disease\n* severe liver and kidney failure\n* dementia, psychiatric diseases, and\u002For preoperative cognitive impairment","FEMALE","99 Years",{"count":47,"type":20},[84],"Background:\n\nVarious analgesic modalities are adopted for perioperative analgesia in breast cancer surgeries. Opioid-free and opioid-sparing techniques are gaining popularity due to the lack of opioid-dependent undesirable effects, including respiratory depression, urinary retention, nausea and vomiting, constipation, itching, opioid-induced hyperalgesia, tolerance, addiction, and immune system disorders.\n\nThe goal of this prospective randomized clinical trial is to investigate the impact of opioid-free anaesthesia (OFA) versus conventional general anaesthesia (CGA) on postoperative analgesic requirements after breast cancer surgery (lumpectomy\u002Fmastectomy, with or without axillary lymph node excision).\n\nSecondary objectives include comparative perioperative evaluation of cognitive function and postoperative adverse events during the first 48 hours atfter surgery. Comparative evaluation of intraoperative haemodynamics and hospital length of stay are also secondary objectives, as well as the incidence of neuropathic pain assessed by validated questionnaires at 3 and 6 months postoperatively.\n\nDuring the preoperative screening, body measurements, age, gender, ASA (American Society of Anesthesiologists) physical status classification, educational level (using a 6-level scale: elementary, middle school, high school, higher education, higher education, and postgraduate\u002Fdoctoral degree), home medication, and comorbidities (using the Charlson Comorbidity Index) are recorded.\n\nIntraoperatively, the duration of anaesthesia, duration of surgery, associated intraoperative data (e.g., haemodynamic instability, adverse effects associated with protocol-administered pharmaceutical agents, etc.), and medications administered (type and quantity) are recorded.\n\nThe investigators expect to recruit at least 100 participants per group.",[112,258,113,24,259,260],"Anesthesia","Opioid Free Anaesthesia","Cancer Recurrence","2026-05-01",{"date":263,"type":29},"2026-05-06",{"date":265,"type":29},"2022-12-28",{"date":267,"type":20},"2027-09-12",{"name":269,"class":36},"University of Ioannina",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":16,"minAge":276,"maxAge":17,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":37},"100617937","interoceptive-awareness-and-function-in-adolescents-with-chronic-pain-100617937","NCT07325110","Interoceptive Awareness and Function in Adolescents With Chronic Pain","Study Group:\n\nInclusion Criteria:\n\n1. Adolescents seen as new patients in the pain clinic at Connecticut Children's\n2. Referred to occupational therapy services.\n3. Adolescents diagnosed with a form of chronic pain.\n4. Between the ages of 11 and 21 years at time of enrollment.\n5. If over 18, the ability to understand and willingness to sign the informed consent document or the ability to use the short form process.\n6. If under 18, the parent\u002Flegal guardian, has the ability to understand and willingness to sign the informed consent document or the ability to use the short form process.\n7. Adolescents between the ages of 11 and less than 18 years with the ability to understand and willingness to sign assent.\n8. Adolescents who agree to therapeutic yoga as a planned part of their occupational therapy treatment plan.\n\nExclusion Criteria:\n\n1. Adolescents not receiving yoga as an element of their occupational therapy treatment plan.\n2. Adolescents with a cognitive impairment that would impede their ability to participate.\n3. Adolescents with a neuromuscular diagnosis, such as Cerebral Palsy, Spinal Muscular Atrophy, and Muscular Dystrophies, that are not appropriate for yoga as an element of their treatment plan for this study.\n4. Adolescents unwilling to complete surveys to participate in this research study.\n5. Adolescents who are currently actively practicing yoga\n6. Adolescents who are currently receiving occupational therapy at another location.","11 Years",{"count":278,"type":20},49,"The main objectives of this study are to compare the levels of interoceptive awareness and self-reported function pre and post completion of an occupational therapy treatment plan. The target population are adolescents aged 11-21 years that are diagnosed with chronic pain and are seen through the Pain Team at Connecticut Children's. The primary aims are:\n\n* To compare the reported levels of interoceptive awareness in adolescents with chronic pain before and after their occupational therapy treatment plan.\n* To compare the reported levels of function in adolescents with chronic pain before and after their occupational therapy treatment plan.",[140,281,24],"Chronic Pain Syndrome",[145,283,284,285,286,287],"adolescents","interoceptive awareness","function","occupational therapy","yoga","2026-04-23",{"date":290,"type":29},"2026-04-27",{"date":292,"type":29},"2026-02-25",{"date":214,"type":20},{"name":97,"class":36},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":82,"phases":302,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":37},"100491865","phase-2-screening-trial-for-pain-relief-in-schwannomatosis-starfish-100491865","NCT05684692","Screening Trial for Pain Relief in Schwannomatosis (STARFISH)","Inclusion Criteria for Master Study:\n\n* Patients must have a confirmed diagnosis schwannomatosis by fulfilling either clinical or molecular diagnosis.\n* Clinical diagnosis: A clinical diagnosis of schwannomatosis is confirmed by either of the two following criteria:\n\n  * Two or more non-intradermal schwannomas, one with pathological confirmation, without evidence of bilateral vestibular schwannoma (see exclusion criteria 3.2.3) OR\n  * one pathologically confirmed schwannoma or intracranial meningioma and\n  * An affected first-degree relative. Molecular diagnosis\n* A molecular diagnosis of schwannomatosis is confirmed by either (1) two or more pathologically proven schwannomas or meningiomas AND genetic studies of at least two tumors with loss of heterozygosity (LOH) for chromosome 22 and two different NF2 mutations; or (2) one pathologically proven schwannoma or meningioma and a germline SMARCB1 or LZTR1 pathogenic mutation.\n* Participant must be ≥ 18 years of age on Day 1 of treatment.\n* Karnofsky performance status ≥ 70 or ECOG PS 0 or 1 (see Appendix A).\n* Subject must have moderate-to-severe pain secondary to SWN, defined as Score ≥5 on the Numeric Rating Scale-11 (NRS-11) as the maximum pain intensity in the previous 7 days.\n* Ability to understand and the willingness to sign written informed consent and assent documents.\n* Must have established relationship with primary care physician and provide contact information.\n\nInclusion Criteria for Sub-study A - Siltuximab or Placebo Arm:\n\n* Participants must be willing and able to provide written informed consent\u002Fassent for the siltuximab arm of the STARFISH trial.\n* Subject must have moderate to severe pain secondary to schwannomatosis, defined as having a median Numeric Rating Scale-11 (NRS-11) score ≥5 during screening.\n* Subject must have insufficient response to, intolerance of, be unwilling to try, or contraindication to medical therapies for SWN-related pain, such as NSAID therapy, opioid treatment, or neuropathic pain medications.\n* Clinical laboratory values as specified below within 28 days before the first dose of study drug:\n\n  * ALT\u002Faspartate aminotransferase (AST) ≤ 2.5 × institutional upper limit of normal (ULN);\n  * Total serum bilirubin ≤ 1.5 × institutional ULN (\\\u003C3.0 × institutional ULN for patients with Gilbert syndrome)\n  * Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m2, using the modification of diet in renal disease (MDRD) equation\n  * Serum lipase ≤1.5 × institutional ULN\n  * Absolute neutrophil count ≥1.5 × 109\u002FL\n  * Platelet count ≥75 × 109\u002FL\n  * Hemoglobin ≥9 g\u002FdL and \\\u003C17 g\u002FdL\n* Female subjects of childbearing potential and at risk for pregnancy (e.g., not abstinent) must agree to use 2 highly effective methods of contraception throughout the study and for 100 days (15 weeks) after the last dose of assigned study medication.\n* Female subjects of non-childbearing potential must meet at least 1 of the following criteria:\n\n  * Have undergone documented total hysterectomy or bilateral oophorectomy\n  * Have medically confirmed ovarian failure\n  * Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; \\[status may be confirmed with\u002Fand have\\] a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state; In the event of indeterminate or anomalous results on pregnancy\u002FFSH testing or issues surrounding contraceptive requirements, the study clinician should be contacted and will make the final decision as to the adequacy\u002Fneed for contraception.\n\nInclusion Criteria for Sub-study B - Erenumab-Aooe or Placebo Arm:\n\n* Participants must be willing and able to provide written informed consent\u002Fassent for the erenumab-aooe arm of the STARFISH trial.\n\n  * Subject must have moderate to severe pain secondary to schwannomatosis, defined as a median NRS-11 Score ≥5 during Screening.\n  * Subject must have insufficient response to, unwillingness to take, intolerance of, or contraindication to at least one medical therapies for SWN-related pain, such as NSAID therapy, opioid treatment, or neuropathic pain medications.\n  * Clinical laboratory values as specified below within 28 days before the first dose of study drug:\n* ALT\u002Faspartate aminotransferase (AST) ≤ 2.5 × institutional upper limit of normal (ULN);\n* Total serum bilirubin ≤ 1.5 × institutional ULN (\\\u003C3.0 × institutional ULN for patients with Gilbert syndrome)\n* Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m2, using the modification of diet in renal disease (MDRD) equation\n* Serum lipase ≤1.5 × institutional ULN\n* Absolute neutrophil count ≥1.5 × 109\u002FL\n* Platelet count ≥75 × 109\u002FL\n* Hemoglobin ≥9 g\u002FdL\n\n  * Female subjects of childbearing potential and at risk for pregnancy (e.g., not abstinent) must agree to use 2 highly effective methods of contraception throughout the study and for 60 days after the last dose of assigned study medication.\n  * Female subjects of non-childbearing potential must meet at least 1 of the following criteria:\n* Have undergone documented total hysterectomy or bilateral oophorectomy\n* Have medically confirmed ovarian failure\n* Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; \\[status may be confirmed with\u002Fand have\\] a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state; In the event of indeterminate or anomalous results on pregnancy\u002FFSH testing or issues surrounding contraceptive requirements, the study clinician should be contacted and will make the final decision as to the adequacy\u002Fneed for contraception.\n\nExclusion Criteria for Master Study:\n\n* Participants who have had chemotherapy within a minimum of 4 weeks prior to Master Study registration (or a minimum of 5 half-lives and resolution to baseline of toxicities unless there are irreversible toxicities from prior drug that do not influence risk of next drug).\n* Participants who are receiving any other investigational agents.\n* Participants with nervous system tumors that, in the opinion of the treating investigator, are likely to require active treatment (including surgery) within 6 months of registration to the Master Study.\n* History of a malignancy in the last 3 years, unless (a) have been disease-free for at least 2 years or (b) are deemed by the treating investigator to be at low risk for progression or recurrence of that malignancy (e.g., carcinoma in situ, basal cell carcinoma, Gleason 6 prostate cancer) in the next 2 years\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n\nExclusion Criteria for Sub-study A - Siltuximab or Placebo Arm:\n\n* Subject has a history of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG fusion protein.\n* The subject's pain is related to a non-schwannomatosis cause such as prior cancer therapy, infection, bowel obstruction\u002Fperforation, spinal cord compression, or fracture or impending fracture of weight bearing bone.\n* Subjects at increased risk for GI perforation including documented history of GI perforation, mesenteric ischemia, or intestinal volvulus; or chronic use of high dose glucocorticoids (particularly in combination with NSAIDs)\n* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n* Treatment with any investigational products within 1 month or 5 half-lives (whichever is longer) before the first dose of study drug\n* Had major surgery within 30 days of the first dose of siltuximab. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.\n* Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\n\n  * Myocardial infarction within 6 months before the first dose of siltuximab.\n  * Unstable angina within 6 months before first dose of siltuximab.\n  * Congestive heart failure within 6 months before first dose of siltuximab.\n  * History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician.\n  * Any history of clinically significant ventricular arrhythmia.\n  * Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose of siltuximab.\n* Have uncontrolled hypertension (defined as an average systolic blood pressure \\> 160 or an average diastolic blood pressure \\> 100 for adults) despite adequate treatment with medications. Patients with hypertension should be under treatment on study entry to control blood pressure.\n* Have an ongoing or active clinically significant infection, including, but not limited to, the requirement for intravenous antibiotics. Note: superficial infections that are treated with topical medications or other infections that, in the opinion of the site PI, are uncomplicated are not considered exclusion criteria.\n* History of a malignancy in the last 3 years, unless (a) have been disease-free for at least 2 years or (b) are deemed by the treating investigator to be at low risk for progression or recurrence of that malignancy (e.g., carcinoma in situ, basal cell carcinoma, Gleason 6 prostate cancer) in the next 2 years.\n* Have a known history of HIV infection. Testing is not required in the absence of history.\n* Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of siltuximab.\n\nExclusion Criteria for Sub-study B - Erenumab-Aooe or Placebo Arm:\n\n* Subject has a history of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG fusion protein\n* Have chronic constipation limiting instrumental activities of daily living (e.g., laundry, dressing, shopping, running errands, and transportation).\n* Have uncontrolled hypertension (defined as an average systolic blood pressure \\> 160 or an average diastolic blood pressure \\> 100) despite adequate treatment with medications. Patients with hypertension should be under treatment on study entry to control blood pressure\n* The subject's pain is related to a non-schwannomatosis cause such as prior cancer therapy, infection, bowel obstruction\u002Fperforation, spinal cord compression, or fracture or impending fracture of weight bearing bone.\n* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol\n* Treatment with any investigational products within 1 month or 5 half-lives (whichever is longer) before the first dose of study drug\n* Had major surgery within 30 days of the first dose of erenumab-aooe. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.\n* Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\n\n  * Myocardial infarction within 6 months before the first dose of erenumab-aooe.\n  * Unstable angina within 6 months before first dose of erenumab-aooe.\n  * Congestive heart failure within 6 months before first dose of erenumab-aooe.\n  * History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician.\n  * Any history of clinically significant ventricular arrhythmia.\n  * Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose of erenumab-aooe.\n* History of a malignancy in the last 3 years, unless (a) have been disease-free for at least 2 years or (b) are deemed by the treating investigator to be at low risk for progression or recurrence of that malignancy (e.g., carcinoma in situ, basal cell carcinoma, Gleason 6 prostate cancer) in the next 2 years.\n* Have a known history of HIV infection. Testing is not required in the absence of history.\n* Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of erenumab-aooe.\n* Participants who are lactating women are excluded from this study because there are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production.",{"count":169,"type":20},[200],"This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN).\n\nThis Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies:\n\n* Investigational Drug Sub-Study A: Siltuximab\n* Investigation Drug Sub-Study B: Erenumab-Aooe",[305,306,24],"Schwannomatosis","Schwannomas",[305,306,308,309,310],"Pain","chronic Pain","Severe Pain","2026-04-20",{"date":288,"type":29},{"date":314,"type":29},"2023-08-31",{"date":316,"type":20},"2027-11-30",{"name":318,"class":36},"Massachusetts General Hospital",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":82,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":37},"100581211","home-based-transcutaneous-auricular-vagus-nerve-stimulation-tavns-for-ibs-pain-100581211","NCT06847360","Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain","Home-Based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Pain and Symptom Management Among Young Adults With Irritable Bowel Syndrome (IBS)","IBS-taVNS","Inclusion Criteria:\n\n* 18 - 29 years of age;\n* Men and women;\n* Diagnosis of IBS from a healthcare provider with current report of pain (volunteers asked to bring provider-verification of IBS diagnosis based on Rome IV criteria to initial study appointment);\n* Experiencing moderate pain (≥3 out of 10 on numeric rating scale \\[NRS\\]) at least 4 days of the week and lasting previous three months;\n* Daily access to a computer connected to the internet; and\n* Able to read and speak English.\n\nExclusion Criteria:\n\n* Other chronic pain condition;\n* Celiac disease or inflammatory bowel disease;\n* Diabetes mellitus;\n* severe psychiatric condition requiring inpatient treatment in previous 6 months;\n* Pregnancy or lactation;\n* Regular use of opioids or other illicit substances;\n* use of probiotics or antibiotics within 2 weeks from enrollment; and\n* any other conditions\u002Fcontraindications that prohibit the application of taVNS including but not limited to any current or past history of cardiovascular disorders, recent ear trauma, and metal implants above the level of the neck.","29 Years",{"count":329,"type":20},80,[84],"The goal of this clinical trial is to learn the feasibility and safety of using home-based taVNS in young adults with IBS to manage their IBS-related pain and symptoms. It will also learn about participants' experience in using the home-based taVNS intervention. The main questions it aims to answer are:\n\n* Is it feasible to use a home-based taVNS intervention for pain and symptom management among YAs with IBS?\n* Is it safe and reported satisfactory to use a home-based taVNS intervention for pain and symptom management among YAs with IBS? Researchers will compare Active to Sham taVNS (a look-alike intervention that contains minimal stimulation) to see if Active taVNS works on managing IBS-related pain and symptoms.\n\nParticipants will:\n\n* Take Active or Sham taVNS intervention for a 6-week treatment (twice daily, 30 minutes per session)\n* Visit the research lab at the initial setup and the end of the 6-week treatment for checkups and tests\n* Keep a diary of their symptoms and the number of times they use the taVNS.",[24,333,334],"Irritable Bowel Syndrome","Symptom Cluster","2026-04-09",{"date":337,"type":29},"2026-04-13",{"date":339,"type":29},"2026-01-19",{"date":341,"type":20},"2028-01",{"name":343,"class":36},"Yale University",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":82,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":71},"100577585","phase-2-pain-reprocessing-therapy-in-post-operative-knee-pain-100577585","NCT06800209","Pain Reprocessing Therapy in Post-Operative Knee Pain","Efficacy and Mechanisms of Pain Reprocessing Therapy in Chronic Post-Operative Knee Pain","REJOICE","Inclusion Criteria:\n\n* Patients are deemed eligible at 3 months post-operatively if: The patient completed a primary knee replacement \\[surgery completed without complication and patient exhibits full mechanical joint function, as determined by the treating physician (good range of motion, stability, and wound healing; absence of swelling)\\] and patient reports last week average knee pain ≥ 4 of 20 and at least two questions rated 'moderate' on A 12-item shortened version (ShortMAC) of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).\n* Reported pre-operative chronic knee pain of at least 6 months duration prior to surgery\n* The procedure was a primary (not a revision) knee replacement\n* Proficient in English\n\nExclusion Criteria:\n\n* Patients who are not willing to participate in a telehealth visit.\n* Patients with pre-op chronic pain but who do not have post-operative pain after the three month time period.\n* Active suicidal ideation with intent, recent history of suicide attempt, or self-harm behaviors within the past 5 years (including non-suicidal self-harm).\n* Recent history of inpatient psychiatric hospitalization within the past 5 years.\n* Active, current psychosis or mania.\n* Active, current substance abuse, or problems with substance abuse within the past 2 years.\n* Instability in living conditions or major interfering life events:\n\n  * Major surgery or other major medical event planned in coming 6 months.\n  * Uncertain whether they will have suitable conditions for telehealth appointments over the next 2 months, including access to a computer or tablet, reliable high-speed internet, and a quiet, comfortable room that is consistently available.\n  * Major, interfering changes in employment or housing anticipated over the next 6 months.\n* Neurological conditions (e.g., Alzheimer's, dementia, mild cognitive impairment, Huntington's disease, multiple sclerosis, cerebral palsy). This will be case-by-case decision made by PI to determine if the condition may interfere with treatment and warrant exclusion.\n* Self-reported diagnosis of an autoimmune disease (e.g., rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus, polymyositis, or another autoimmune disorder).\n* Currently or plan to be involved in lawsuits related to pain in next 6 months, currently or plan to apply for any disability payments related to the pain in next 6 months, or received legal settlement or other disability payments related to the pain over past 2 years.\n\nEEG Exclusion Criteria (patients can still be enrolled as long as they meet all other eligibility criteria; however, they will not undergo EEG testing):\n\n* Are unable or uncomfortable with completing a dry cap EEG.\n* Has had a history of abnormal EEGs.\n* Had bilateral TKA",{"count":353,"type":20},110,[200],"The goal of this clinical trial is to learn whether Pain Reprocessing Therapy (PRT) can help adults with knee pain after knee replacement surgery. The study is comparing PRT to usual care (the regular treatment people get after surgery) to see which works better for relieving pain.\n\nThe main questions the study aims to answer are:\n\n1. Does PRT help lower pain in people who have chronic knee pain after knee surgery?\n2. How do the effects of PRT compare with usual care in terms of pain relief and other factors such as anxiety, depression, and sleep?\n3. How does PRT impact the brain?\n\nParticipants will:\n\n1. Be randomly assigned to receive either PRT or usual care.\n2. Complete questionnaires about their pain and health.\n3. If in the PRT group, have eight weekly therapy sessions over video calls with a therapist.\n4. If interested, may also take part in an optional EEG test to measure brain activity related to pain.",[24,357],"Knee Pain Chronic",[145,359,360,361,362,363,364,365,366],"Pain Reprocessing Therapy","knee pain","total knee replacement","Total Knee Arthroplasty","mind-body","mindfulness","TKA","PRT","2026-03-30",{"date":369,"type":29},"2026-03-31",{"date":371,"type":29},"2025-08-13",{"date":373,"type":20},"2028-09-29",{"name":375,"class":36},"University of Colorado, Denver",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":16,"minAge":79,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":244},"100543018","adolescent-outcomes-of-post-operative-opioid-exposure-100543018","NCT06350409","Adolescent Outcomes of Post-operative Opioid EXposure","APEX","Adolescent Inclusion Criteria\n\n1. Adolescents between the ages of 12 to 17 years old, inclusive, who are scheduled to undergo a scheduled surgical procedure with a greater than 90% likelihood of requiring opioid analgesia for at least 48 hours post-operatively (as an inpatient) or discharged home with at least a 48-hour supply of prescription opioids.\n\n   • Opioid prescribing practices vary by institution; therefore, eligible surgical procedures will be determined on a site-by-site basis.\n2. Adolescents willing and able to provide informed assent and have a parent\u002Fcaregiver willing to provide informed consent.\n\nParent\u002FCaregiver Inclusion Criteria\n\n1. Parent or legal guardian of an eligible adolescent.\n2. Parent or legal guardian willing and able to provide written informed consent.\n\nAdolescent Exclusion Criteria\n\nAdolescents meeting any of the following criteria will be excluded from study participation:\n\n1. Adolescents who have been prescribed opioids in the past 2 years for pain due to a chronic medical condition.\n2. Adolescents who have a current chronic medical condition that requires ongoing opioid pain management and treatment such as sickle cell disease, arthritis, or cancer.\n3. Adolescents who do not have a caregiver who is willing to co-participate in the study.\n4. Adolescents who cannot speak or read English at a 4th-grade level as determined by medical or research staff.\n5. Adolescents who are currently in the custody of the Department of Youth Services, jail\u002Fprison, or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities.\n6. Adolescents who are currently in the custody of the Department of Children and Families or living with a foster family.\n7. Adolescents who are currently pregnant or parenting.\n8. Adolescents that self or parent report of ever having been diagnosed with opioid use disorder, or prescribed buprenorphine, methadone, or naltrexone to treat opioid use disorder.\n9. Adolescents who are currently enrolled in an intervention study that aims to impact opioid prescription or pain management pre-, peri-, or post-operatively.\n\nParent\u002FCaregiver Exclusion Criteria\n\nParents\u002FCaregivers meeting any of the following criteria will be excluded from study participation:\n\n1. Parents\u002FCaregivers who cannot speak or read English or Spanish at a 4th grade level as determined by medical or research staff.\n2. Parents\u002FCaregivers that are currently incarcerated.\n3. Parents\u002FCaregivers that are in physical or mental distress that precludes study participation as determined by clinical or study staff.","17 Years",{"count":385,"type":20},20000,"The goal of this observational study is to examine the factors associated with the transition from medical exposure to opioids with \"signposts\" of future opioid use disorder among adolescent surgical patients. The main question aims to identify factors (moderators, mediators, and covariates) associated with risk factors for opioid use disorder (ROUD) in the 12 months following major surgery with opioid exposure among adolescents aged 12-17. Participants will be asked to complete electronic surveys pre- and post-operatively and approve the collection of peri-operative data from the Electronic Medical Record to assess correlations.",[388,24],"Opioid Use Disorder",[390,391],"Adolescent Opioid Use","Post operative pain","2026-03-16",{"date":394,"type":29},"2026-03-18",{"date":396,"type":29},"2024-11-12",{"date":398,"type":20},"2028-02",{"name":400,"class":36},"Sharon Levy",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":252,"minAge":45,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":82,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100608140","ultrasound-guided-pecs-block-and-ketamine-infusion-for-preventing-chronic-pain-in-patients-undergoing-breast-cancer-surgery-100608140","NCT07197684","Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery","Effect of Ultrasound Guided Pecs Block With Intravenous Ketamine and Ketamine Infusion Alone For Prevention of Chronic Post-Surgical Pain in Patients Undergoing Breast Cancer Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult female patients with breast cancer aged between 18-75 years\n* ASA (American Society of Anesthesia) physical status I, II, and III\n* Patients scheduled for elective breast cancer surgery (Mastectomy with or without axillary clearance)\n\nExclusion Criteria:\n\n* Refusal to participate or withdrawal of informed consent\n* Surgical procedures involving breast reconstruction with flaps or implants\n* Patient scheduled for bilateral mastectomy\n* Reoperation on the same side due to cancer recurrence\n* Known allergy or contraindication to study drugs\n* History of severe psychiatric illness (e.g., major depression, bipolar disorder, schizophrenia)\n* Chronic opioid use, substance abuse, or opioid addiction\n* Pre-existing chronic pain or neuropathic pain disorders\n* Coagulopathy, anticoagulation therapy, or localized infection at the site of block\n* Uncontrolled hypertension and ischemic heart disease","75 Years",{"count":135,"type":20},[84],"The goal of this clinical trial is to is to compare the effectiveness of ultrasound-guided Pecs block with intravenous ketamine versus intravenous ketamine infusion alone in preventing Chronic Post-Surgical Pain (CPSP) in patients undergoing breast cancer surgery. The main question it aims to answer is,\n\nHow effective is the ketamine and ketamine with pecs block in reducing the frequency of Chronic Post-Surgical Pain after breast cancer surgery",[112,24,413],"Post Surgical Pain","2026-02-17",{"date":416,"type":29},"2026-02-19",{"date":392,"type":20},{"date":419,"type":20},"2027-05-01",{"name":421,"class":36},"Aga Khan University",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":252,"minAge":17,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":82,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":37},"100536367","stellate-ganglion-block-for-prevention-of-post-mastectomy-depression-100536367","NCT06263907","Stellate Ganglion Block for Prevention of Post Mastectomy Depression","Preemptive Efficacy of Stellate Ganglion Block for Prevention of Post Mastectomy Depression","SGB","Inclusion Criteria:\n\n* Female patients\n* Age ranging from 18 to 65 years\n* American Society of Anesthesiologists (ASA) no more than II\n* Had unilateral cancer breast\n* Scheduled to do unilateral modified radical mastectomy\n\nExclusion Criteria:\n\n* Pregnant female\n* Existing Horner syndrome\n* Had any neuromuscular disease\n* Had allergy to local anesthetics\n* History of use of analgesics\n* Had any deformity or a previous surgery in the neck or ipsilateral arm or breast\n* Had any contraindication to the procedure (coagulation disorders, local infection, sepsis)\n* Had any contraindication to the sympathetic blockade (decompensate cardiopulmonary or hemodynamic disorders)\n* History of psychotic disorder including depression, bipolar disorder or personality disorder\n* Patient with Beck Depression Inventory (BDI) score more than 13","65 Years",{"count":432,"type":20},140,[84],"Complications after mastectomy include chronic pain and depression.",[436,437,24],"Mastectomy","Pain, Acute","2026-02-15",{"date":414,"type":29},{"date":441,"type":29},"2024-03-01",{"date":443,"type":20},"2028-12-30",{"name":445,"class":36},"Mansoura University",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":82,"phases":454,"briefSummary":455,"conditions":456,"keywords":460,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":37},"100537392","nutrition-care-in-patients-living-with-chronic-pain-100537392","NCT06277232","Nutrition Care in Patients Living With Chronic Pain","Developing Nutrition Care Integrated Into Pain Rehabilitation: a Feasibility and Non-Randomized, Controlled Quasi-Experimental Study","Inclusion Criteria:\n\n* Self reported Body Mass Index (BMI)\\>=25;\n* Written consent to participate and attend to the pain rehabilitation program due to disabling chronic pain (on sick leave or experiencing major interference in daily life due to chronic pain)\n* Agreement not to participate in other parallel treatments for weight reduction\n* Not currently using medications of weight reduction\n* Available to get access to internet via own mobile\u002Fcellphone.\n\nExclusion Criteria:\n\n* Health conditions such as pregnancy, active metabolic disease, rheumatoid arthritis, and serious psychiatric disease (investigator's judgement, eg, psychosis or suicidal ideation);\n* Coagulation disorders with predisposition to bleeding, medication with anticoagulants (low- dose aspirin is permitted);\n* hypersensitivity to anaesthetic\n* Difficulties in understanding the Swedish language.",{"count":47,"type":20},[84],"The investigators' purpose is to develop and test the feasibility, usability, and satisfaction of the Diet4painrelief app as a platform for implementing nutrition care in a specialist pain rehabilitation clinic. The Diet4painrelief will consist of two components: a) a screening tool for nutrition status b) an individually tailored behavior change program aiming to improve the dietary habits and behaviors of patients living with chronic pain.\n\nPart I: Included 20 patients with complex chronic pain to examine the feasibility and outcomes of evidence-based Interdisciplinary Pain Rehabilitation Program (IPRP) integrated with nutrition care. The Diet4painrelief includes a screening tool to assess basic nutritional status as well as their intake of key unhealthy and healthy foods and drinks (through three 24hour-dietary recordings or food diary). Thereafter, the patients receive a personalized behavior change program for dietary optimization. The investigators will design and adapt 6 modules in the digital platform (Diet4painrelief app) based on the International Association for the Study of Pain (IASP) recommendations (6 aspects about 'nutrition and pain') and Sweden's food culture. Clinical outcomes using patient-reported data on socio-demographics, pain aspects, psychometric data, physical disability, and quality of life will be measured at three occasions: first appointment (Pre-IPRP), immediately after completing the rehabilitation program (Post-IPRP), and at a 12-month follow-up (FU-IPRP). Blood samples will be taken to identify biomarkers at the same occasions that provide objective information on metabolic and nutritional abnormalities and further to evaluate the effect of the dietary intervention on changing of pain rehabilitation outcomes.\n\nPart II: Included 192 patients with complex chronic pain. Half of the participants receive IPRP and nutrition care (described above) and the other half receive standard IPRP.",[457,458,459,24],"Nutrition Poor","Overweight and Obesity","Mobile Phone Use",[461,462,463,464],"Chronic pain","Nutrition care","Pain rehabilitation","eHealth","2026-02-13",{"date":467,"type":29},"2026-02-18",{"date":469,"type":29},"2024-08-01",{"date":471,"type":20},"2028-12-31",{"name":473,"class":474},"Linkoeping University","OTHER_GOV",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":82,"phases":485,"briefSummary":486,"conditions":487,"keywords":492,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":37},"100529040","evaluating-the-efficacy-of-the-pain-identification-and-communication-toolkit-100529040","NCT06168604","Evaluating the Efficacy of the Pain Identification and Communication Toolkit","The Pain Identification and Communication Toolkit: A Training Program to Support Family Caregivers of Persons With ADRD","PICT","CAREGIVER PARTICIPANTS\n\nInclusion Criteria:\n\n1. Age 21 or older\n2. Any gender\n3. English speaking\n4. Cognitively intact (BOMC ≤10)\n5. Provides care to a community-dwelling adult with dementia or cognitive impairment who also has a pain diagnosis\n6. Care recipient is not enrolled in hospice\n7. Visits the care recipient at least weekly\n8. Accessible by telephone\n\nExclusion Criteria:\n\n1. Paid caregiver\n2. Age 20 or younger\n3. Non-English speaking\n4. Cognitively impaired\n5. Does not provide care to a person with dementia or cognitive impairment who also has a pain diagnosis\n6. Currently enrolled in hospice\n7. The patient to whom the caregiver provides assistance is enrolled in hospice\n8. Visits care recipient less than weekly\n9. Not accessible by telephone.\n\nPATIENT PARTICIPANTS\n\nInclusion Criteria:\n\n1. Residing in community settings\n2. Record of dementia or cognitive impairment\n3. Diagnosis of pain\n4. Responsive to environment\n5. No terminal illness with life expectancy \\\u003C6 months\n6. Not in active cancer treatment\n\nExclusion Criteria:\n\n1. Lives in a residential facility (such as a nursing home or assisted living)\n2. Enrolled in hospice\n3. No dementia or cognitive impairment\n4. Unresponsive to environment\n5. Has terminal illness with life expectancy \\\u003C6 months\n6. Are in active cancer treatment",{"count":484,"type":20},440,[84],"This study will evaluate the Pain Identification and Communication Toolkit (PICT), a multicomponent intervention for caregivers of people with Alzheimer's disease and related dementias (ADRD). PICT provides training in observational pain assessment and coaching in effective pain communication techniques. It will recruit participants from programs of all-inclusive care for the elderly (PACE) and partnering health care clinics. The investigators hypothesize that PICT will help caregivers to recognize and communicate about pain in their care recipients.",[488,489,490,491,24],"Caregiver Burden","Cognitive Impairment","Dementia","Alzheimer Disease",[493,494,490,308],"Family Caregivers","Informal Caregivers","2026-02-09",{"date":497,"type":29},"2026-02-12",{"date":499,"type":29},"2023-12-14",{"date":501,"type":20},"2027-10-30",{"name":503,"class":36},"Weill Medical College of Cornell University",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":37},"100415252","diabetic-neuropathy-in-spinal-cord-stimulator-patients-100415252","NCT04687215","Diabetic Neuropathy in Spinal Cord Stimulator Patients","Spinal Cord Stimulation Improves Pain, Arterial Stiffness and Vascular Flow in Lower Extremities in Patients With Diabetes Mellitus Type II A Multidisciplinary Collaborative Prospective Study","Inclusion Criteria:\n\n1. Patients with DM type 2 of more than 1-year duration\n2. DM stage 3 or less\n3. Patients ≥18 years of age\n4. Refractory painful diabetic peripheral neuropathy of the lower extremities\n5. ABI index \\\u003C0.9\n\nExclusion Criteria:\n\n1. Patients on anticoagulants\n2. Patients with active infections\n3. Patients with HbA1\\>10\n4. Psychiatric disorders and cognitive dysfunctions\n5. Illicit Drug Usage\n6. Patients on dialysis\n7. BMI\\>35.0\n8. Surgery within the last 30 days\n9. Ulcer of the lower extremities\n10. Calcification of the peripheral arteries",{"count":7,"type":20},"The objective of this study is to assess the effect Spinal Cord Stimulators have toward improving vascular changes of diabetes mellitus in patients eligible for SCS placement based on their condition of painful diabetic neuropathy; we will evaluate improving their disability and quality of life, improving micro-circulatory changes induced by Diabetes Mellitus (DM), improving macro-circulatory changes induced by DM and improving arterial stiffness of the vessels of the lower extremity.",[514,515,516,517,518,519,24],"Diabetes Mellitus","Neuropathy","Neuropathic Pain","Vascular Diseases","Vascular Stiffness","Microvascular Changes","2026-02-03",{"date":522,"type":29},"2026-02-05",{"date":524,"type":29},"2022-01-27",{"date":526,"type":20},"2026-12-01",{"name":528,"class":36},"University of Chicago",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":16,"minAge":430,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":82,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":37},"100580481","phase-2-prescription-opioids-brain-structure-and-cognition-in-older-adults-with-chronic-pain-100580481","NCT06837857","Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain","Imaging, Cognition, and Opioids in Older Adults With Chronic Pain (I-COAP) Trial","I-COAP","Inclusion Criteria:\n\n* 65 years of age or older\n* Pain for longer than 3 months (chronic)\n* Moderate to severe pain nearly every day (averaged PEG score \\>5)\n* Persistent pain despite use of \\>1 analgesic (Tylenol, Ibuprofen, lidocaine patch, etc)\n\nExclusion Criteria:\n\n* Untreated severe\u002Funcontrolled Mental health (schizophrenia, bipolar disorder, psychosis, history of suicidality, depression or anxiety, PTSD)\n* Severe liver (cirrhosis) or kidney disease (ESRD on dialysis or GFR\\\u003C 30)\n* Cognitive impairment (Kokmen Short Test of Mental Status score \\\u003C 29)\n* Life expectancy \\\u003C 12 months\n* Contraindications to MRI\n* Non-English speaking\n* Opioid use within the past 6 months\n* Contraindications or previous intolerance to prescription opioids\n* Substance use disorder or high-risk for opioid-related adverse effects (Opioid Risk Tool ≥ 8)\n* Residence outside of Minnesota or Wisconsin during opioid intervention period\n* Another pain generator that is greater than their knee or shoulder or low back pain\n* Anticipated surgery for joint replacement (Knee or shoulder) sooner than 3 months.",{"count":47,"type":20},[200],"The purpose of this study is to determine whether exposure to prescription opioids is associated with brain structural changes on magnetic resonance imaging (MRI), with the primary outcome of white matter integrity as measured by fractional anisotropy of the corpus callosum.",[24],"2026-01-07",{"date":543,"type":29},"2026-01-08",{"date":545,"type":29},"2025-04-16",{"date":547,"type":20},"2029-12-31",{"name":549,"class":36},"Mayo Clinic",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":557,"sex":16,"minAge":558,"maxAge":559,"enrollmentInfo":560,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":562,"conditions":563,"keywords":569,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":37},"100396242","fmri-and-ivcm-cornea-microscopy-of-cxl-in-keratoconus-100396242","NCT04439552","fMRI and IVCM Cornea Microscopy of CXL in Keratoconus","Neuroplasticity of Pain Pathways and Corneal Afferent Regeneration Following Corneal Crosslinking (CXL) in Keratoconus","Inclusion Criteria:\n\nCXL Group\n\n* Age 8-35 years\n* Clinical diagnosis of keratoconus and seeking CXL treatment\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nControl Group\n\n* Age 8-35 years\n* No diagnosis of keratoconus\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nExclusion Criteria (Both Groups):\n\n* Claustrophobic\n* Weight \\> 285 lbs (weight limit of the MRI table)\n* Significant medical history, including:\n\nCurrent DSM-IV-TR axis I psychiatric disorders. Chronic pain Significant head injury Seizures Brain tumor Cerebrovascular accident Neurological disease aside from migraine HIV-AIDs Prescription medication strongly implicated in causing dry eyes\n\n* Magnetic implants or metal-containing tattoos on their chest or above\n* Pregnancy\n* History of contact lens wear\n* Any allergic response to a numbing eyedrop in the past",true,"8 Years","35 Years",{"count":561,"type":20},60,"Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).",[113,24,437,564,565,566,567,568],"Surgical Injury","Surgical Wound","Cornea Injury","Cornea","Keratoconus",[570,571,572,573],"fMRI","Corneal Microscopy","IVCM","Neuroimaging","2025-12-15",{"date":576,"type":29},"2025-12-19",{"date":578,"type":29},"2021-10-04",{"date":580,"type":20},"2027-12",{"name":582,"class":36},"Boston Children's Hospital",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":252,"minAge":591,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":82,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":37},"100450537","a-study-to-reduce-persistent-post-mastectomy-pain-using-opioid-free-anesthesia-100450537","NCT05146778","A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia","A Single-blinded Randomized-controlled Study to Reduce Persistent Post-mastectomy Pain Using Multimodal Opioid-free Anesthesia","RELIEF","Inclusion Criteria:\n\n* All of patients will undergo mastectomy with or without immediate breast reconstruction.\n\nExclusion Criteria:\n\n* Previous history of breast surgery\n* Allergy to drug\n* Other cancer history\n* Underlying psychologic disorder\n* Patients with chronic pain requiring pain killers\n* Baseline SpO2 \\\u003C95%\n* Left ventricular EF \\\u003C40%\n* Bradycardia as HR \\\u003C50 bpm\n* BMI \\>35kg\u002Fm2\n* Pregnant woman","19 Years","80 Years",{"count":594,"type":20},230,[84],"In 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated at 1 year after mastectomy based on the Breast Cancer Pain Questionnaire (BCPQ). Baseline pain sensitivity test and psychologic evaluation will be done before operation.",[112,436,24,598],"Pain, Post Operative","2025-11-18",{"date":601,"type":29},"2025-11-21",{"date":603,"type":29},"2021-12-16",{"date":605,"type":20},"2027-10-31",{"name":607,"class":36},"Gangnam Severance Hospital",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":16,"minAge":430,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":617,"conditions":618,"keywords":621,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":37},"100244658","evaluation-of-the-pacepacenet-bhl-clinical-program-100244658","NCT02463266","Evaluation of the PACE\u002FPACENET BHL Clinical Program","SUSTAINIV","Inclusion Criteria:\n\n1. Aged 65 and older, males and females.\n2. Participating in the SUSTAIN Clinical Program\n3. For the 6 Month Outcome Research Evaluation, in addition to meeting criteria 1 and 2, willing to provide verbal informed consent to participate in the 6 Month Outcome Research Evaluation at the end of the acute phase of clinical care, usually at three months.\n\nExclusion Criteria:\n\n* Not meeting the inclusion criteria listed above.",{"count":616,"type":20},4000,"The SUpporting Seniors Receiving Treatment And INtervention (SUSTAIN) program is a telephone-based clinical service designed to help identify and manage behavioral health issues among PACE\u002FPACENET enrollees. The purpose of the current project is to a) explore moderators of treatment response among beneficiaries in the SUSTAIN Clinical Program and b) to evaluate the sustained clinical effects of the program.",[619,620,24],"Depression","Anxiety",[622,623,619],"Primary Care","Elderly","2025-09-16",{"date":626,"type":29},"2025-09-22",{"date":628,"type":4},"2014-03",{"date":630,"type":20},"2026-12",{"name":632,"class":36},"University of Pennsylvania",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":16,"minAge":640,"maxAge":383,"enrollmentInfo":641,"targetDuration":4,"studyType":82,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":37},"100491306","sleep-pain-and-stress-in-adolescents-with-persistent-pain-100491306","NCT05677412","Sleep, Pain and Stress in Adolescents With Persistent Pain","PedPainSleep","Inclusion Criteria:\n\n* Patients aged 15-17 years with persistent (\\> 3months) pain reporting average pain intensity over 3\u002F10 on the Numerical Rating Scale (NRS).\n\nExclusion Criteria:\n\n* ongoing medication for sleep or pain.","15 Years",{"count":642,"type":20},20,[84],"The main aim is the gain information of sleep structures in adolescents with persistent pain. Also to study simple interventions to support their sleep and pain management. The main aim of this study is to test the efficacy and feasibility of suggestive presleep relaxation technique in improving sleep quality and sleep-related emotional memory processing.",[24,646],"Sleep","2025-09-09",{"date":649,"type":29},"2025-09-15",{"date":651,"type":29},"2023-05-23",{"date":653,"type":20},"2026-06-30",{"name":655,"class":36},"Helsinki University Central Hospital",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":16,"minAge":45,"maxAge":104,"enrollmentInfo":664,"targetDuration":4,"studyType":82,"phases":666,"briefSummary":667,"conditions":668,"keywords":674,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":37},"100505741","ultrasound-guided-percutaneous-intercostal-nerve-cryoneurolysis-for-analgesia-following-traumatic-rib-fracture-100505741","NCT05865327","UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture","UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture, a Pilot Randomized Control Trial (UNPIN Trial)","UNPIN","Inclusion Criteria:\n\n* Aged ≥18\n* Unilateral traumatic rib fractures (3 to 8)\n* Candidate for ESP block catheter\n* Within 48hrs of admission to hospital\n\nExclusion Criteria:\n\n* Lack of patient consent; unlikely to comply with follow up\n* Unable to use Patient Controlled Regional Analgesia (Ventilated\u002Fsedated patients or Moderate to severe traumatic brain injury)\n* Chronic pain (opioid use \\> 30mg oral morphine equivalent per day)\n* Substance use disorder\n* CrCl \\\u003C 50\n* BMI \\> 45\n* Significant distracting injuries (unreduced long bone fractures, unstable pelvic or spine fractures and patients requiring trauma laparotomy- also preclude positioning for block placement (lateral decubitus or sitting up))\n* Contraindications for ESP catheter placement (pre-existing medical\u002Fneurological\u002Fhematologic diseases, localized infection\u002Ftrauma at site of intervention, allergy to amide local anesthetics)\n* Contraindications to CN (cryoglobulinemia, paroxysmal cold hemoglobinuria, multiple myeloma and cold urticarial).\n* Unable to return to Trauma Recovery Clinic (in-person or virtual) at 3 months",{"count":665,"type":20},24,[84],"Traumatic rib fractures (i.e., broken ribs caused by a physical injury) are common and very painful. They also often lead to serious complications, more time spent in hospital, and can even lead to death. Even after rib fractures have healed, they can lead to long-term pain and a lower quality of life.\n\nA technology called cryoneurolysis, which acts to freeze nerves causing pain using a small tool which can turn very cold, is a promising new way to manage rib fracture pain. This study is a test with a small number of people to see if it is feasible to use this technology for patients with rib fractures. If this is successful, we will recruit more people for a larger study to see if cryoneurolysis, along with standard pain control techniques, is better at stopping pain, compared to just the normal techniques alone. Participants in our study will be asked to rate their pain, and record pain medications that they take for 3 months after their pain procedure.",[669,670,671,308,437,24,672,673],"Rib Fractures","Rib Fracture Multiple","Rib; Fracture, With Flail Chest","Trauma","Trauma Injury",[675,676,677],"Cryoneurolysis","Rib Fracture Pain","Intercostal Nerve Block","2025-09-05",{"date":680,"type":29},"2025-09-12",{"date":682,"type":29},"2023-10-23",{"date":684,"type":20},"2025-12",{"name":686,"class":36},"Sunnybrook Health Sciences Centre"]